<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1262">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144724</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00115050</org_study_id>
    <nct_id>NCT05144724</nct_id>
  </id_info>
  <brief_title>Volume Targeted Ventilation in the Delivery Room</brief_title>
  <official_title>Volume Targeted Ventilation in the Delivery Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot trial to assess the feasibility of volume Targeted Ventilation in the&#xD;
      Delivery Room.&#xD;
&#xD;
      Preterm infants will be randomized to pressure guided or volume targeted ventilation during&#xD;
      respiratory support in the delivery room&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of preterm infants receiving the intervention</measure>
    <time_frame>Through study completion (total 18 months)</time_frame>
    <description>Number of Participants who have received allocated treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neonatal Respiratory Distress</condition>
  <arm_group>
    <arm_group_label>Volume Targeted Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Positive pressure ventilation will be provided using a set tidal volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pressure guided Ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Positive pressure ventilation will be provided using a set peak inflation pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Volume targeted ventilation</intervention_name>
    <description>Positive pressure ventilation will be provided using a set tidal volume</description>
    <arm_group_label>Volume Targeted Ventilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pressure targeted ventilation</intervention_name>
    <description>Positive pressure ventilation will be provided using a set peak inflation pressure</description>
    <arm_group_label>Pressure guided Ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preterm infants 23-28 weeks' gestation requiring respiratory support at birth will be&#xD;
             eligible for the trial. Inclusion criteria are pragmatic to enable the inclusion of&#xD;
             ELGAN infants (Extremely Low Gestational Age Newborns).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants will be excluded if they have a congenital abnormality or condition that might&#xD;
             have an adverse effect on breathing or ventilation (e.g., congenital diaphragmatic&#xD;
             hernia), or congenital heart disease requiring intervention in the neonatal period.&#xD;
&#xD;
          -  Infants will also be excluded if their parents refuse to give consent to this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Minute</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Schmölzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg Schmölzer, MD, PhD</last_name>
    <phone>+17807354647</phone>
    <email>georg.schmoelzer@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brenda Law, MD, MSc</last_name>
    <phone>+17807354647</phone>
    <email>blaw2@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Georg SCHMOLZER</last_name>
      <phone>7807354647</phone>
      <email>georg.schmoelzer@me.com</email>
    </contact>
    <investigator>
      <last_name>Georg Schmolzer</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Po-Yin Cheung</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Fray</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brenda Law</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The protocol will be published in an open access journal and data can be requested from the principal investigator</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Protocol will be published within 18 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

